Entrada Therapeutics, Inc.

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary technology platform called Endosomal Escape Vehicle (EEV) therapeutics. The platform is designed to deliver therapeutic molecules—including RNA and protein-based drugs—across cellular membranes to intracellular targets that have historically been difficult to access. By enabling efficient intracellular delivery, the company aims to expand the range of treatable diseases and improve therapeutic outcomes relative to existing treatment approaches.

The company's development portfolio focuses on RNA- and protein-based programs for neuromuscular and ocular diseases. The EEV platform operates as a modular delivery system applicable across multiple therapeutic modalities and organ systems, allowing Entrada to pursue a diversified pipeline rather than a single indication or drug class.

Entrada operates as a private research organization with approximately 183 full-time employees and is headquartered in Boston, Massachusetts. The company is incorporated in Delaware and trades on the Nasdaq exchange. As a clinical-stage enterprise, Entrada generates no material product revenue and operates primarily through capital raises to fund ongoing research and development activities.